Achilles Therapeutics plc

NasdaqGS:ACHL Stock Report

Market Cap: US$32.1m

Achilles Therapeutics Management

Management criteria checks 2/4

Achilles Therapeutics' CEO is Iraj Ali, appointed in Jan 2018, has a tenure of 6.33 years. total yearly compensation is $1.70M, comprised of 27.3% salary and 72.7% bonuses, including company stock and options. directly owns 2.71% of the company’s shares, worth $869.62K. The average tenure of the management team and the board of directors is 6.3 years and 4 years respectively.

Key information

Iraj Ali

Chief executive officer

US$1.7m

Total compensation

CEO salary percentage27.3%
CEO tenure6.3yrs
CEO ownership2.7%
Management average tenure6.3yrs
Board average tenure4yrs

Recent management updates

Recent updates

Is Achilles Therapeutics (NASDAQ:ACHL) In A Good Position To Deliver On Growth Plans?

Feb 26
Is Achilles Therapeutics (NASDAQ:ACHL) In A Good Position To Deliver On Growth Plans?

Here's Why We're Watching Achilles Therapeutics' (NASDAQ:ACHL) Cash Burn Situation

Nov 13
Here's Why We're Watching Achilles Therapeutics' (NASDAQ:ACHL) Cash Burn Situation

Here's Why We're Watching Achilles Therapeutics' (NASDAQ:ACHL) Cash Burn Situation

Jul 19
Here's Why We're Watching Achilles Therapeutics' (NASDAQ:ACHL) Cash Burn Situation

Is Achilles Therapeutics (NASDAQ:ACHL) In A Good Position To Deliver On Growth Plans?

Mar 11
Is Achilles Therapeutics (NASDAQ:ACHL) In A Good Position To Deliver On Growth Plans?

Here's Why We're Watching Achilles Therapeutics' (NASDAQ:ACHL) Cash Burn Situation

Nov 18
Here's Why We're Watching Achilles Therapeutics' (NASDAQ:ACHL) Cash Burn Situation

Achilles-led group gets €4M funding for personalized cell therapy manufacturing

Jul 21

Is Achilles Therapeutics (NASDAQ:ACHL) In A Good Position To Invest In Growth?

Apr 13
Is Achilles Therapeutics (NASDAQ:ACHL) In A Good Position To Invest In Growth?

Achilles Therapeutics (NASDAQ:ACHL) Is In A Good Position To Deliver On Growth Plans

Dec 27
Achilles Therapeutics (NASDAQ:ACHL) Is In A Good Position To Deliver On Growth Plans

Here's Why We're Not Too Worried About Achilles Therapeutics' (NASDAQ:ACHL) Cash Burn Situation

Sep 09
Here's Why We're Not Too Worried About Achilles Therapeutics' (NASDAQ:ACHL) Cash Burn Situation

CEO Compensation Analysis

How has Iraj Ali's remuneration changed compared to Achilles Therapeutics's earnings?
DateTotal CompensationSalaryCompany Earnings
Dec 31 2023US$2mUS$463k

-US$70m

Compensation vs Market: Iraj's total compensation ($USD1.70M) is above average for companies of similar size in the US market ($USD667.63K).

Compensation vs Earnings: Insufficient data to compare Iraj's compensation with company performance.


CEO

Iraj Ali (48 yo)

6.3yrs

Tenure

US$1,698,000

Compensation

Dr. Iraj Ali, Ph.D. serves as Chief Executive Officer at Achilles Therapeutics Plc since December 10, 2018 and served as its Interim Chief Executive Officer since January 2018 until December 10, 2018. Dr....


Leadership Team

NamePositionTenureCompensationOwnership
Iraj Ali
CEO & Director6.3yrsUS$1.70m2.71%
$ 869.6k
Karl Peggs
Founder & Chief Medical Officerno datano data1.36%
$ 437.9k
Sergio Quezada
Founder & Chief Scientific Officer8.3yrsno data1.12%
$ 361.1k
Robert Coutts
Chief Financial Officer3.5yrsno data0.66%
$ 210.8k
Mark Lowdell
Founder8.3yrsno datano data
Charles Swanton
Founder8.3yrsno datano data
Lee Stern
Vice President of Investor Relations & External Communications3.4yrsno datano data
Daniel Carey Hood
General Counsel & Company Secretary1.5yrsno datano data
Julia Wilson
Head of Communicationsno datano datano data
Tariq Ahmed
Executive Vice President of Peopleno datano datano data
Edward Samuel
Executive Vice President of Technical Operationsno datano datano data
Shree Patel
Executive Vice President of Supply Operationsno datano datano data

6.3yrs

Average Tenure

49yo

Average Age

Experienced Management: ACHL's management team is seasoned and experienced (6.3 years average tenure).


Board Members

NamePositionTenureCompensationOwnership
Iraj Ali
CEO & Director8.2yrsUS$1.70m2.71%
$ 869.6k
Edwin Moses
Independent Chairman of the Board5.4yrsUS$379.00k0.55%
$ 176.9k
Carsten Boess
Independent Non-Executive Director4.1yrsUS$176.00k0%
$ 0
Bernhard R. Ehmer
Non-Executive Director2.1yrsUS$106.00k0%
$ 0
Markwin Velders
Member of Scientific Advisory Board3yrsno datano data
Scott Antonia
Member of Scientific Advisory Board4yrsno datano data
Michael Giordano
Independent Non-Executive Director5.7yrsUS$189.00k0.11%
$ 36.5k
Elizabeth Jaffee
Member of Scientific Advisory Board4yrsno datano data
Christopher Klebanoff
Member of Scientific Advisory Board4yrsno datano data
Julie O'Neill
Non-Executive Director3yrsUS$102.00k0%
$ 0
Alena Gros
Member of Scientific Advisory Board2.3yrsno datano data
Ben Creelan
Member of Scientific Advisory Board2.3yrsno datano data

4.0yrs

Average Tenure

61yo

Average Age

Experienced Board: ACHL's board of directors are considered experienced (4 years average tenure).


Simply Wall Street Pty Ltd (ACN 600 056 611), is a Corporate Authorised Representative (Authorised Representative Number: 467183) of Sanlam Private Wealth Pty Ltd (AFSL No. 337927). Any advice contained in this website is general advice only and has been prepared without considering your objectives, financial situation or needs. You should not rely on any advice and/or information contained in this website and before making any investment decision we recommend that you consider whether it is appropriate for your situation and seek appropriate financial, taxation and legal advice. Please read our Financial Services Guide before deciding whether to obtain financial services from us.